Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 2/20 | 0.30 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577568 | 0.84 | FNTA (0.39) | FNTAFNTBMAT2APTAFRPARP15 | |
| SCHEMBL29909362 | 0.79 | PTGS2 (0.40) | FNTAFNTBNPC1RAB9A | |
| SCHEMBL29909922 | 0.79 | FNTA (0.41) | FNTAFNTBCCR9MAT2APTAFR | |
| SCHEMBL29909627 | 0.79 | FNTA (0.35) | FNTAFNTBCCR9MAT2APTAFR | |
| SCHEMBL23577059 | 0.79 | FNTA (0.41) | FNTAFNTBCCR9MAT2APTAFR | |
| SCHEMBL23576821 | 0.79 | FNTA (0.35) | FNTAFNTBCCR9MAT2APTAFR | |
| SCHEMBL29909241 | 0.78 | TNF (0.34) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23576830 | 0.78 | TNF (0.34) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23600528 | 0.78 | FNTA (0.38) | FNTAFNTBCCR9MAT2APTAFR | |
| SCHEMBL29909757 | 0.78 | FNTA (0.38) | FNTAFNTBCCR9MAT2APTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | FNTA 968/4885FNTB 743/4885KDM4E 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.